Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Serum eosinophils as a COPD biomarker: ready for prime time?

Literature DB >> 27066738

Serum eosinophils as a COPD biomarker: ready for prime time?

Anand S Iyer¹, Mark T Dransfield².

Abstract

Mesh：

Substances：
Biomarkers

Year: 2016 PMID： 27066738 PMCID： PMC6516479 DOI： 10.1016/S2213-2600(16)30040-6

Source DB: PubMed Journal: Lancet Respir Med ISSN： 2213-2600 Impact factor: 30.700

× No keyword cloud information.

11 in total

1. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.

Authors: Steven Pascoe; Nicholas Locantore; Mark T Dransfield; Neil C Barnes; Ian D Pavord
Journal: Lancet Respir Med Date: 2015-04-12 Impact factor: 30.700

2. The many "small COPDs": COPD should be an orphan disease.

Authors: Stephen I Rennard; Jørgen Vestbo
Journal: Chest Date: 2008-09 Impact factor: 9.410

3. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease.

Authors: Salman H Siddiqui; Alessandro Guasconi; Jørgen Vestbo; Paul Jones; Alvar Agusti; Pierluigi Paggiaro; Jadwiga A Wedzicha; Dave Singh
Journal: Am J Respir Crit Care Med Date: 2015-08-15 Impact factor: 21.405

4. Chronic obstructive pulmonary disease phenotypes: the future of COPD.

Authors: MeiLan K Han; Alvar Agusti; Peter M Calverley; Bartolome R Celli; Gerard Criner; Jeffrey L Curtis; Leonardo M Fabbri; Jonathan G Goldin; Paul W Jones; William Macnee; Barry J Make; Klaus F Rabe; Stephen I Rennard; Frank C Sciurba; Edwin K Silverman; Jørgen Vestbo; George R Washko; Emiel F M Wouters; Fernando J Martinez
Journal: Am J Respir Crit Care Med Date: 2010-06-03 Impact factor: 21.405

5. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.

Authors: Fernando J Martinez; Peter M A Calverley; Udo-Michael Goehring; Manja Brose; Leonardo M Fabbri; Klaus F Rabe
Journal: Lancet Date: 2015-02-13 Impact factor: 79.321

6. Can we predict sputum eosinophilia from clinical assessment in patients referred to an adult asthma clinic?

Authors: E Yap; W M Chua; L Jayaram; I Zeng; A C Vandal; J Garrett
Journal: Intern Med J Date: 2013-01 Impact factor: 2.048

7. Withdrawal of inhaled glucocorticoids and exacerbations of COPD.

Authors: Helgo Magnussen; Bernd Disse; Roberto Rodriguez-Roisin; Anne Kirsten; Henrik Watz; Kay Tetzlaff; Lesley Towse; Helen Finnigan; Ronald Dahl; Marc Decramer; Pascal Chanez; Emiel F M Wouters; Peter M A Calverley
Journal: N Engl J Med Date: 2014-09-08 Impact factor: 91.245

8. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial.

Authors: Mona Bafadhel; Susan McKenna; Sarah Terry; Vijay Mistry; Mitesh Pancholi; Per Venge; David A Lomas; Michael R Barer; Sebastian L Johnston; Ian D Pavord; Christopher E Brightling
Journal: Am J Respir Crit Care Med Date: 2012-03-23 Impact factor: 21.405

9. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD.

Authors: Ian D Pavord; Sally Lettis; Nicholas Locantore; Steve Pascoe; Paul W Jones; Jadwiga A Wedzicha; Neil C Barnes
Journal: Thorax Date: 2015-11-19 Impact factor: 9.139

10. Overtreatment of COPD with inhaled corticosteroids--implications for safety and costs: cross-sectional observational study.

Authors: Patrick White; Hannah Thornton; Hilary Pinnock; Sofia Georgopoulou; Helen P Booth
Journal: PLoS One Date: 2013-10-23 Impact factor: 3.240

3 in total